ACWActinogen Medical Limited

ACW Stock Price, Valuation & Chart | Actinogen Medical Limited

Compare

$0.040+0.00 (+4.88%)

At close · 02 Sept 2026, 05:31 am

Sector: Healthcare ACW intrinsic value ACW calculated fair value vs price Website

Overview Financials Dividends Ratios

ACW Historical price chart

ACW Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization159.85M

PE Ratio-7.47

EPS-0.01

Trading Volume3.37M

Today's High/Low0.04/0.04

Dividend Yield0.00

52 Week High/Low0.07/0.03

Shares Outstanding3.72B

ACW Financial Statement

ACW Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 1 analyst giving stock ratings to ACW in the past 3 months.

ACW Analysis & performance metrics

ACW Company profile

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in…

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive…

ACW Management team

Name

Position

Andrew B. Udell B.Sc., M.B.A.

Chief Commercial Officer

Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.

Company Secretary

William Edward Souter BCom, IPAA, LLB (Adel)CFO

Chief Financial Officer

Dana C. Hilt M.D.

Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board

Michael Roberts

Head of Investor Relations & Corporate Communications

Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.

Head of Clinical Pharmacology & Lead Physician and Depression

Fujun Li Ph.D.

Head of Manufacturing

Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.CEO

MD, Chief Executive Officer & Director

Name

Position

Andrew B. Udell B.Sc., M.B.A.

Chief Commercial Officer

Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.

Company Secretary

William Edward Souter BCom, IPAA, LLB (Adel)CFO

Chief Financial Officer

Dana C. Hilt M.D.

Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board

Michael Roberts

Head of Investor Relations & Corporate Communications

Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.

Head of Clinical Pharmacology & Lead Physician and Depression

Fujun Li Ph.D.

Head of Manufacturing

Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.CEO

MD, Chief Executive Officer & Director

Management Team

Andrew B. Udell B.Sc., M.B.A.

Chief Commercial Officer

Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.

Company Secretary

William Edward Souter BCom, IPAA, LLB (Adel)CFO

Chief Financial Officer

Dana C. Hilt M.D.

Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board

Michael Roberts

Head of Investor Relations & Corporate Communications

Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.

Head of Clinical Pharmacology & Lead Physician and Depression

Fujun Li Ph.D.

Head of Manufacturing

Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.CEO

MD, Chief Executive Officer & Director

Management

Andrew B. Udell B.Sc., M.B.A.

Chief Commercial Officer

Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.

Company Secretary

William Edward Souter BCom, IPAA, LLB (Adel)CFO

Chief Financial Officer

Dana C. Hilt M.D.

Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board

Michael Roberts

Head of Investor Relations & Corporate Communications

Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.

Head of Clinical Pharmacology & Lead Physician and Depression

Fujun Li Ph.D.

Head of Manufacturing

Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.CEO

MD, Chief Executive Officer & Director

Total 8 executives

ACW Frequently asked questions

What is Actinogen Medical Limited (ACW) Stock Price?

Current stock price of Actinogen Medical Limited (ACW) stock is $0.040. The stock price is +4.88% higher in the session. The intraday range can be seen from this page. Volume of Actinogen Medical Limited (ACW) stock is 3.37M.

Last updated at 02 Sept 2026, 05:31 am.

Why is the Actinogen Medical Limited (ACW) stock price going up or down today?

The stock price of Actinogen Medical Limited (ACW) can change with earnings, company news, and overall market sentiment. Actinogen Medical Limited operates in the Healthcare / Unknown market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Actinogen Medical Limited stock expensive at its current price?

Whether Actinogen Medical Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ACW on this page is -7.47. EPS on this page is -0.01. Compare those figures with peers and growth expectations before deciding if the current Actinogen Medical Limited price is justified.

How has the stock price of Actinogen Medical Limited (ACW) performed historically?

Historical performance for Actinogen Medical Limited (ACW) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ACW reacted to past earnings and market events.

Should I buy Actinogen Medical Limited (ACW) stock, at this price?

Buying Actinogen Medical Limited (ACW) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.